Category Archives: Big pharma

Old dogs and new tricks: The real-world consequences of excluding older adults from drug trials

How much time do you spend with old people? That’s a loaded question, of course. Age is a relative term, since we age every day and so does the world’s population. Even though the global median age was estimated at…

Share

Where’s Superman When He’s Needed?

Look! Up in the sky! It’s a bird! It’s a plane! It’s . . . another superbug. The invasion of the multidrug-resistant superbugs is not a nightmare in the making. It’s already here. And it could be years before a…

Share

Patent Cliff Doom, Gloom Not Panning Out

A lot of ink has flowed describing the tough times that big pharma companies are experiencing as each, lemming-like, tumbles off the patent cliff. Certainly, the pain of shrinking revenues is clear for all to see. AstraZeneca plc, for example,…

Share

Is it Better to Forgive and Pharm-merge?

Aug. 5 was International Forgiveness Day, and the founding organization of this annual effort, Worldwide Forgiveness Alliance (WFA), says in its mission statement that a goal is to promote and publicize the research findings that show forgiveness creates better health,…

Share

The Star-Struck FTC

The FTC seems to have come down with a bad case of star envy. Not content with its supporting role as implementer of laws duly passed by Congress, the agency is intent on rewriting the script, casting itself as headliner…

Share

Mamma Mia! It’s Biopharma Season!

“Hey kids, let’s put on a show!” That was a famous line from the 1937 Broadway musical, Babes in Arms, shouted to exhort the old gang to take action to save the orphanage. As the theater market just put on…

Share

Profit vs. Value: When Activist Shareholders Attack

Amylin Pharmaceuticals Inc.’s board dodged a dissident shareholder bullet three years ago, but the San Diego-based biotech is back in the crosshairs of billionaire investor and activist shareholder Carl Icahn, who again is seeking to nominate a new slate of…

Share

And the Bio-Oscar Goes to . . .

I have a fondness for the movies and I perform a function in the biotechnology market, so it’s a bonus when I can combine the two. I’ve written about the correlation between the movie and drug businesses before, so indulge…

Share

Licensing or Acquisition? Big Pharma Shares How They (and YOU) Decide

When I was at the Biocom Global Life Science Partnering Conference last week, one of the more interesting debates I heard was about whether it’s better to in-license an asset or acquire the whole company. While every case is different…

Share

Like Warren Buffett, J&J Throws Down Incubator Gauntlet . . .Who’s Next?

When people talk about Johnson and Johnson’s new San Diego incubator, Janssen Labs, they can’t help but be a little bit skeptical about the fact that J&J isn’t taking any options or first-rights to compounds developed by its incubator tenants….

Share